254 Results
GeneStrat blood-based mutation testing for advanced lung cancer offers significant advantages for patients and their treating physicians over standard tissue testing, which can delay treatment.
Results from an exploratory analysis suggest VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone.
Randomised Proteomic Stratified Phase III Study of Second Line Erlotinib Versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer (PROSE)
Biodesix, Inc and Inivata announced a partnership today to develop and commercialize Next Generation Sequencing (NGS)-blood based tests for lung cancer.
The paper’s authors conclude that using VeriStrat improves overall survival and decreases medical costs in the US payer system.
A new study published in Current Medical Research and Opinion shows that VeriStrat changes treatment decisions for patients with lung cancer.
A recent study published in the peer-reviewed journal Managed Care affirms VeriStrat; demonstrates the value of the VeriStrat lung cancer test
Biodesix data on proteomic and genomic blood-based assays presented at EORTC
Biodesix and Progenetics have entered into an international agreement; Biodesix tests will be available in Israel for the first time.
VeriStrat blood-based prognostic and predictive proteomics test has been approved for in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer (NSCLC).
